{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:06:15Z","timestamp":1792800375669,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Clinical Capacity Enhancement Project of the First Affiliated Hospital of Nanjing Medical University, the Pukou District Social Cause Science and Technology Development Project in 2020","award":["S2020-21"],"award-info":[{"award-number":["S2020-21"]}],"id":[{"id":"https:\/\/ror.org\/04py1g812","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Pukou Branch Hospital of Jiangsu Province Hospital (Nanjing Pukou Central Hospital) Major Project of Science and Technology Development Fund in 2021","award":["KJ2021-1"],"award-info":[{"award-number":["KJ2021-1"]}],"id":[{"id":"https:\/\/ror.org\/04py1g812","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2023ZD0501500"],"award-info":[{"award-number":["2023ZD0501500"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82125033, 82230110, and 82388102"],"award-info":[{"award-number":["82125033, 82230110, and 82388102"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15623-0","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T07:14:16Z","timestamp":1770016456000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Longitudinal plasma proteome profiling identifies IFN-gamma dynamics as a time-dependent predictor of immunotherapy response in advanced gastric cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Jingshuai","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiwang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiufen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangfu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"issue":"10251","key":"15623_CR1","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(20)31288-5.","journal-title":"Lancet"},{"issue":"11","key":"15623_CR2","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nrclinonc.2015.132","volume":"12","author":"SG Thrumurthy","year":"2015","unstructured":"Thrumurthy SG, Chaudry MA, Chau I, Allum W. Does surgery have a role in managing incurable gastric cancer? Nat Rev Clin Oncol. 2015;12(11):676\u201382. https:\/\/doi.org\/10.1038\/nrclinonc.2015.132.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"15623_CR3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364. https:\/\/doi.org\/10.1038\/nrc3239.","journal-title":"Nat Rev Cancer"},{"issue":"10111","key":"15623_CR4","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"Y-K Kang","year":"2017","unstructured":"Kang Y-K, Boku N, Satoh T, Ryu M-H, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(17)31827-5.","journal-title":"Lancet"},{"issue":"6","key":"15623_CR5","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","volume":"17","author":"K Muro","year":"2016","unstructured":"Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17(6):717\u201326. https:\/\/doi.org\/10.1016\/S1470-2045(16)00175-3.","journal-title":"Lancet Oncol"},{"issue":"5","key":"15623_CR6","doi-asserted-by":"publisher","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4(5):e180013. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0013.","journal-title":"JAMA Oncol"},{"issue":"3","key":"15623_CR7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133\u201350. https:\/\/doi.org\/10.1038\/s41568-019-0116-x.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"15623_CR8","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.annonc.2020.07.002","volume":"31","author":"V Subbiah","year":"2020","unstructured":"Subbiah V, Solit DB, Chan TA, Kurzrock R. The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) \u226510: a decision centered on empowering patients and their physicians. Ann Oncol. 2020;31(9):1115\u20138. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.002.","journal-title":"Ann Oncol"},{"issue":"2","key":"15623_CR9","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein RM, Lee C-H, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202\u20136. https:\/\/doi.org\/10.1038\/s41588-018-0312-8.","journal-title":"Nat Genet"},{"issue":"1","key":"15623_CR10","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41467-021-20935-9","volume":"12","author":"C Valero","year":"2021","unstructured":"Valero C, Lee M, Hoen D, Weiss K, Kelly DW, Adusumilli PS, et al. Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat Commun. 2021;12(1):729. https:\/\/doi.org\/10.1038\/s41467-021-20935-9.","journal-title":"Nat Commun"},{"issue":"1","key":"15623_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","volume":"2","author":"J McLaughlin","year":"2016","unstructured":"McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol. 2016;2(1):46\u201354. https:\/\/doi.org\/10.1001\/jamaoncol.2015.3638.","journal-title":"JAMA Oncol"},{"issue":"6","key":"15623_CR12","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1158\/2326-6066.CIR-16-0329","volume":"5","author":"J Zhou","year":"2017","unstructured":"Zhou J, Mahoney KM, Giobbie-Hurder A, Zhao F, Lee S, Liao X, et al. Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade. Cancer Immunol Res. 2017;5(6):480\u201392. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0329.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"15623_CR13","doi-asserted-by":"publisher","first-page":"1832348","DOI":"10.1080\/2162402X.2020.1832348","volume":"9","author":"L Incorvaia","year":"2020","unstructured":"Incorvaia L, Fanale D, Badalamenti G, Porta C, Olive D, De Luca I, et al. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions. Oncoimmunology. 2020;9(1):1832348. https:\/\/doi.org\/10.1080\/2162402X.2020.1832348.","journal-title":"Oncoimmunology"},{"issue":"3","key":"15623_CR14","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.4110\/in.2020.20.e27","volume":"20","author":"DH Kang","year":"2020","unstructured":"Kang DH, Park C-K, Chung C, Oh I-J, Kim Y-C, Park D, et al. Baseline serum interleukin-6 levels predict the response of patients with advanced non-small cell lung cancer to PD-1\/PD-L1 inhibitors. Immune Netw. 2020;20(3):e27. https:\/\/doi.org\/10.4110\/in.2020.20.e27.","journal-title":"Immune Netw"},{"key":"15623_CR15","doi-asserted-by":"publisher","unstructured":"Baba\u010di\u0107 H, Lehti\u00f6 J, Pico de Coa\u00f1a Y, Pernemalm M, Eriksson H. In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma. J Immunother Cancer. 2020;8(1). https:\/\/doi.org\/10.1136\/jitc-2019-000204.","DOI":"10.1136\/jitc-2019-000204"},{"issue":"1","key":"15623_CR16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41392-024-01773-9","volume":"9","author":"X Chen","year":"2024","unstructured":"Chen X, Xu H, Chen X, Xu T, Tian Y, Wang D, et al. First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study. Signal Transduct Target Ther. 2024;9(1):73. https:\/\/doi.org\/10.1038\/s41392-024-01773-9.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"15623_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"issue":"20","key":"15623_CR18","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1709937.","journal-title":"N Engl J Med"},{"issue":"1","key":"15623_CR19","doi-asserted-by":"publisher","first-page":"5476","DOI":"10.1038\/s41467-023-40829-2","volume":"14","author":"Y-N Kim","year":"2023","unstructured":"Kim Y-N, Park B, Kim JW, Kim BG, Kim SW, Kim HS, et al. Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01\/APGOT-OV4. Nat Commun. 2023;14(1):5476. https:\/\/doi.org\/10.1038\/s41467-023-40829-2.","journal-title":"Nat Commun"},{"issue":"16","key":"15623_CR20","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.1158\/1078-0432.CCR-14-3220","volume":"21","author":"EQ Lee","year":"2015","unstructured":"Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, Wong ET, et al. A multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma patients. Clin Cancer Res. 2015;21(16):3610\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-3220.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"15623_CR21","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1158\/1078-0432.CCR-24-1934","volume":"31","author":"C Xu","year":"2025","unstructured":"Xu C, Mannucci A, Esposito F, Oliveres H, Alonso-Ordu\u00f1a V, Yubero A, et al. An exosome-based liquid biopsy predicts depth of response and survival outcomes to Cetuximab and Panitumumab in metastatic colorectal cancer: the EXONERATE study. Clin Cancer Res. 2025;31(6):1002\u201315. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1934.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"15623_CR22","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1373\/clinchem.2018.298323","volume":"65","author":"R Meddeb","year":"2019","unstructured":"Meddeb R, Pisareva E, Thierry AR. Guidelines for the preanalytical conditions for analyzing circulating cell-free DNA. Clin Chem. 2019;65(5):623\u201333. https:\/\/doi.org\/10.1373\/clinchem.2018.298323.","journal-title":"Clin Chem"},{"issue":"Suppl 1","key":"15623_CR23","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.1038\/modpathol.2014.127","volume":"28","author":"WS Samowitz","year":"2015","unstructured":"Samowitz WS. Evaluation of colorectal cancers for Lynch syndrome: practical molecular diagnostics for surgical pathologists. Mod Pathol. 2015;28(Suppl 1):S109\u201313. https:\/\/doi.org\/10.1038\/modpathol.2014.127.","journal-title":"Mod Pathol"},{"issue":"6","key":"15623_CR24","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/S1470-2045(10)70209-6","volume":"12","author":"W De Roock","year":"2011","unstructured":"De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2011;12(6):594\u2013603. https:\/\/doi.org\/10.1016\/S1470-2045(10)70209-6.","journal-title":"Lancet Oncol"},{"issue":"2","key":"15623_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1001\/jamaoncol.2017.4182","volume":"4","author":"V Prasad","year":"2018","unstructured":"Prasad V, Kaestner V, Mailankody S. Cancer drugs approved based on biomarkers and not tumor type-FDA approval of pembrolizumab for mismatch repair-deficient solid cancers. JAMA Oncol. 2018;4(2):157\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2017.4182.","journal-title":"JAMA Oncol"},{"issue":"9","key":"15623_CR26","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","volume":"24","author":"ST Kim","year":"2018","unstructured":"Kim ST, Cristescu R, Bass AJ, Kim K-M, Odegaard JI, Kim K, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449\u201358. https:\/\/doi.org\/10.1038\/s41591-018-0101-z.","journal-title":"Nat Med"},{"issue":"9","key":"15623_CR27","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","volume":"24","author":"DR Gandara","year":"2018","unstructured":"Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24(9):1441\u20138. https:\/\/doi.org\/10.1038\/s41591-018-0134-3.","journal-title":"Nat Med"},{"issue":"12","key":"15623_CR28","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1093\/annonc\/mdy417","volume":"29","author":"S Kruger","year":"2018","unstructured":"Kruger S, Heinemann V, Ross C, Diehl F, Nagel D, Ormanns S, et al. Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer. Ann Oncol. 2018;29(12):2348\u201355. https:\/\/doi.org\/10.1093\/annonc\/mdy417.","journal-title":"Ann Oncol"},{"issue":"23","key":"15623_CR29","doi-asserted-by":"publisher","first-page":"38056","DOI":"10.18632\/oncotarget.16935","volume":"8","author":"N Guibert","year":"2017","unstructured":"Guibert N, Mazieres J, Delaunay M, Casanova A, Farella M, Keller L, et al. Monitoring of KRAS-mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma. Oncotarget. 2017;8(23):38056\u201360. https:\/\/doi.org\/10.18632\/oncotarget.16935.","journal-title":"Oncotarget"},{"issue":"5","key":"15623_CR30","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1158\/1078-0432.CCR-20-2891","volume":"27","author":"HJ Chalfin","year":"2021","unstructured":"Chalfin HJ, Pramparo T, Mortazavi A, Niglio SA, Schonhoft JD, Jendrisak A, et al. Circulating tumor cell subtypes and T-cell populations as prognostic biomarkers to combination immunotherapy in patients with metastatic genitourinary cancer. Clin Cancer Res. 2021;27(5):1391\u20138. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2891.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"15623_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12943-020-1141-9","volume":"19","author":"X Zhong","year":"2020","unstructured":"Zhong X, Zhang H, Zhu Y, Liang Y, Yuan Z, Li J, et al. Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy. Mol Cancer. 2020;19(1):15. https:\/\/doi.org\/10.1186\/s12943-020-1141-9.","journal-title":"Mol Cancer"},{"issue":"3","key":"15623_CR32","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","volume":"22","author":"AM Gocher","year":"2022","unstructured":"Gocher AM, Workman CJ, Vignali DAA. Interferon-\u03b3: teammate or opponent in the tumour microenvironment? Nat Rev Immunol. 2022;22(3):158\u201372. https:\/\/doi.org\/10.1038\/s41577-021-00566-3.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"15623_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/cas.13424","volume":"109","author":"K Mimura","year":"2018","unstructured":"Mimura K, Teh JL, Okayama H, Shiraishi K, Kua L-F, Koh V, et al. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Cancer Sci. 2018;109(1):43\u201353. https:\/\/doi.org\/10.1111\/cas.13424.","journal-title":"Cancer Sci"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15623-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15623-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15623-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:06:12Z","timestamp":1772582772000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15623-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15623"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15623-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki, and received primary ethical approval from the Institutional Review Board of Nanjing Medical University (Approval No.: NJMUIRB (2021) 589). Additional specific approvals were obtained from The First Affiliated Hospital of Nanjing Medical University (Approval Nos.: 2020-SR-002 and 2020-SR-558) to cover the clinical data collection procedures conducted at that institution. Written informed consent was obtained from all participants prior to their inclusion in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"314"}}